Heike Daldrup-Link

Publication Details

  • Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Gillis, A. M., Sutton, E., DeWitt, K. D., Matthay, K. K., Weinberg, V., Fisch, B. M., Chan, A., Gooding, C., Daldrup-Link, H., Wara, W. M., Farmer, D. L., Harrison, M. R., Haas-Kogan, D. 2007; 69 (3): 858-864

    Abstract:

    To review a historical cohort of consecutively accrued patients with high-risk neuroblastoma treated with intraoperative radiotherapy (IORT) to determine the therapeutic effect and late complications of this treatment.Between 1986 and 2002, 31 patients with newly diagnosed high-risk neuroblastoma were treated with IORT as part of multimodality therapy. Their medical records were reviewed to determine the outcome and complications. Kaplan-Meier probability estimates of local control, progression-free survival, and overall survival at 36 months after diagnosis were recorded.Intraoperative radiotherapy to the primary site and associated lymph nodes achieved excellent local control at a median follow-up of 44 months. The 3-year estimate of the local recurrence rate was 15%, less than that of most previously published series. Only 1 of 22 patients who had undergone gross total resection developed recurrence at the primary tumor site. The 3-year estimate of local control, progression-free survival, and overall survival was 85%, 47%, and 60%, respectively. Side effects attributable to either the disease process or multimodality treatment were observed in 7 patients who developed either hypertension or vascular stenosis. These late complications resulted in the death of 2 patients.Intraoperative radiotherapy at the time of primary resection offers effective local control in patients with high-risk neuroblastoma. Compared with historical controls, IORT achieved comparable control and survival rates while avoiding many side effects associated with external beam radiotherapy in young children. Although complications were observed, additional analysis is needed to determine the relative contributions of the disease process and specific components of the multimodality treatment to these adverse events.

    View details for DOI 10.1016/j.ijrobp.2007.04.006

    View details for Web of Science ID 000249943000030

    View details for PubMedID 17517478

Stanford Medicine Resources:

Footer Links: